Literature DB >> 9672052

Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

R Rosenheck1, J Tekell, J Peters, J Cramer, A Fontana, W Xu, J Thomas, W Henderson, D Charney.   

Abstract

BACKGROUND: This study examines the role of participation in psychosocial treatment as a mediator of the clinical effectiveness of clozapine.
METHODS: Subjects participated in a 12-month double-blind random-assignment trial comparing clozapine and haloperidol in patients hospitalized 30 to 364 days for refractory schizophrenia at 15 Department of Veterans Affairs medical centers. A broker-advocate case management intervention was used to facilitate participation in psychosocial treatments and to document such participation.
RESULTS: Between those who continued receiving clozapine (n=122) or a conventional antipsychotic drug (n=169) for 12 months, those receiving clozapine were more likely to participate in psychosocial rehabilitation treatment. Although they were no more likely to receive clinical recommendations for such treatments, they were more likely to both verbally accept recommendations and to act on them. Structural equation modeling shows that participation in psychosocial treatment did not play a mediating role in clozapine's effect on outcomes at 6 months, but was associated with both reduced symptoms and improved quality of life at 12 months.
CONCLUSIONS: Clozapine facilitates participation in psychosocial treatment, and such enhanced participation is associated with improved quality-of-life and symptom outcomes. Psychosocial rehabilitation should be offered concomitantly with clozapine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9672052     DOI: 10.1001/archpsyc.55.7.618

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  8 in total

1.  A dual change model of life satisfaction and functioning for individuals with schizophrenia.

Authors:  Melissa Edmondson; Rohini Pahwa; Karen Kyeunghae Lee; Maanse Hoe; John S Brekke
Journal:  Schizophr Res       Date:  2012-05-14       Impact factor: 4.939

Review 2.  Treating cognitive dysfunction in patients with schizophrenia.

Authors:  C A Galletly; C R Clark; A C MacFarlane
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 3.  [Evidence basis of psychotherapy for schizophrenia patients in Germany].

Authors:  B Puschner; R Vauth; F Jacobi; T Becker
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

Review 4.  Psychosocial treatments to promote functional recovery in schizophrenia.

Authors:  Robert S Kern; Shirley M Glynn; William P Horan; Stephen R Marder
Journal:  Schizophr Bull       Date:  2009-01-27       Impact factor: 9.306

5.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

Review 6.  Clozapine versus typical neuroleptic medication for schizophrenia.

Authors:  Adib Essali; Nahla Al-Haj Haasan; Chunbo Li; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

7.  Functional recovery in patients with schizophrenia: recommendations from a panel of experts.

Authors:  Guillermo Lahera; José L Gálvez; Pedro Sánchez; Miguel Martínez-Roig; J V Pérez-Fuster; Paz García-Portilla; Berta Herrera; Miquel Roca
Journal:  BMC Psychiatry       Date:  2018-06-05       Impact factor: 3.630

8.  Novel research translates to clinical cases of schizophrenic and cocaine psychosis.

Authors:  João V Nunes; Patricia A Broderick
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.